Tarsus Pharmaceuticals 

TARS NASDAQ
Overview Stats Financials News

Quarterly Financials

Values in thousands 2024-03-31 2023-12-31 2023-09-30 2023-06-30
Revenue $27,614 $13,076 $1,871 $15,277
Gross Profit 25,960 11,860 1,494 14,961
EBITDA -37,684 -44,103 -40,935 -30,460
EBIT -37,954 -44,450 -41,179 -30,642
Net Income -35,731 -41,902 -39,148 -31,424
Net Change In Cash 27,614 13,076 1,871 15,277
Cost of Revenue 40,776
Free Cash Flow -37,963 -35,335 -36,737 -24,613
Cash 193,705 224,947 226,672 106,773
Basic Shares 35,300 31,944 30,622 26,815

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue $17,447 $25,816 $57,027 $33,432
Gross Profit 15,854 24,861 54,952 -246
EBITDA -142,281 -59,127 -10,579 -26,902
EBIT -143,158 -62,712 -12,157 -26,998
Net Income -135,893 -62,091 -13,827 -26,811
Net Change In Cash 17,447 25,816 57,027 33,432
Cost of Revenue -99,672 3,183 110,177
Free Cash Flow -122,995 -49,536 3,162 -21,594
Cash 224,947 71,660 171,332 168,129
Basic Shares 29,383 24,619 20,554 20,323

Earnings Calls

Quarter EPS
2024-03-31 -$1.01
2023-12-31 -$1.31
2023-09-30 -$1.28
2023-06-30 -$1.17